FUS2

N-alpha-acetyltransferase that specifically mediates the acetylation of the acidic amino terminus of processed forms of beta- and gamma-actin (ACTB and ACTG, respectively) (PubMed:29581253, PubMed:30028079). N-terminal acetylation of processed beta- and gamma-actin regulates actin filament depolymerization and elongation (PubMed:29581253). In vivo, preferentially displays N-terminal acetyltransferase activity towards acid N-terminal sequences starting with Asp-Asp-Asp and Glu-Glu-Glu (PubMed:29581253, PubMed:30028079). In vitro, shows high activity towards Met-Asp-Glu-Leu and Met-Asp-Asp-Asp (PubMed:10644992, PubMed:29581307). May act as a tumor suppressor (PubMed:10644992).

Auroneurodental syndrome

ANDS

An autosomal recessive syndrome characterized by progressive high-frequency sensorineural hearing loss, craniofacial dysmorphism, developmental delay and mild proximal and axial muscle weakness.

None

The disease is caused by variants affecting the gene represented in this entry.

Belongs to the acetyltransferase family.

Strongly expressed in heart and skeletal muscle, followed by brain and pancreas, with weak expression in kidney, liver, and lung and no expression in placenta.

• Cytoplasm
• Cytosol

FUS2, NAT6, NAA80, N-alpha-acetyltransferase 80, HsNAAA80, N-acetyltransferase 6, Protein fusion-2, Protein fus-2

• entrezGene:24142
• omim:607073
• swissprot:Q93015

Proteins

31445Da